Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Dr Andrew A. Parsons
Director of Reciprocal Minds Limited & Chairman of Pharmasum Therapeutics AS
About the author:
Dr Andrew A Parsons initially trained as a Pharmacologist and Neuroscientist and has over 90 peer reviewed publications, several patents and contributed to Educational Books in Science and Medicine. His former scientific focus was in areas of neuroplasticity and neurodegeneration. He played key roles on individual projects from initial idea through development and the market place. Working across traditional organisational and cultural boundaries he was instrumental in creating External Innovation platforms within a large Pharma company. Through this he became interested the impact of Human Factors on operational processes. He is a member of the Pharmaceutical Special Interest group and an associate member of the Chartered Institute of Ergonomics and Human Factors.
He is the Director of Reciprocal Minds Limited which supports individuals and groups undergoing personal and professional development and challenges to health and wellbeing. He is the co-author of “Leading with Presence, what it is, why it matters and how to get it?” He is also the Chairman of Pharmasum Therapeutics AS, an early stage Biotech company.
Posts by Dr Andrew A. Parsons
Posted on October 13th, 2017 in Pharma R&D
If there ever was a children’s game that would help prepare the next generation of pharmaceutical R&D scientists and researchers, it would be Snakes and Ladders (Chutes and Ladders in the US). Continue reading “Snakes (aka Chutes) and Ladders – failures and opportunities” »
Posted on October 3rd, 2017 in Pharma R&D
It was not so long ago that there was a perception that the biopharma industry was consolidating and becoming leaner and more focused in its operations, moving to a regional hotspot model Continue reading “From mega-merger to big bang?” »
Posted on September 6th, 2017 in Pharma R&D
Opinions matter; they can drive our behaviors. Within the context of Pharma R&D, it is important to harness the benefits of different views, to think outside the box, innovate and beat the safety of group thinking.
Posted on August 14th, 2017 in Pharma R&D
To maximize value to payers, patients, and practitioners, pharma R&D wants to ensure that new medicines are given to the right patient, at the right time and at the right dose. To do this appropriately, we need ways to classify or diagnose patient groups.